HBP:CC - Helix BioPharma Corp. Reports Voting Results

(TheNewswire)

January 18, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX:HBP)(“Helix” or the “Company”), a clinical-stage biopharmaceuticalcompany developing unique therapies in the field of immuno-oncology,based on its proprietary technological platform DOS47, today announcedthe voting results of the Company’s annual and general meeting ofshareholders held on January 18, 2024 (the “Meeting”).

There were 34 shareholders represented in person or byproxy at the Meeting holding 94,199,707 common shares, representingapproximately 43.48 % of Helix’s total issued and outstandingshares. Below is a summary of the results of matters voted on at theMeeting.

1. Election of Directors

Each of the nominees for election as directors listedin Helix’s management information circular dated December 18, 2023,was elected as a director of Helix for the ensuing year or until theirsuccessors are elected or appointed. Management received proxies inrespect of the election of directors of Helix as follows:

2. Appointment of Auditor

Clearhouse LP was appointed auditor of Helix until thenext annual meeting of shareholders at remuneration to be fixed by thedirectors. Management received proxies in respect of the appointmentof the auditor of Helix as follows:

3. Proposed Consolidation

The proposed amendment to the articles of the Companyto provide that the authorized capital of the Company be altered byconsolidating all of the issued and outstanding Shares on the basis ofa ratio to be determined by the Board, in its sole discretion, withina range of one (1) post- consolidation common share for up to twenty(20) pre-consolidation was approved.

Management received proxies in respect of the proposedconsolidation of common shares of Helix as follows:

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stagebiopharmaceutical company developing unique therapies in the field ofimmune-oncology for the prevention and treatment of cancer based onour proprietary technological platform DOS47. Helix is listed on the TSX underthe symbol “HBP”.

For more information, please contact:

Helix BioPharma Corp.

Suite 2704, 401 Bay Street Toronto, Ontario, M5H 2Y4

Tel: 905-841-2300

Namrata Malhotra, CorporateSecretary

namrata@grovecorp.ca

Forward-LookingStatements and Risks and Uncertainties

This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47 . Forward-looking statements can further be identified by the use offorward-looking terminology such as “ongoing”, “estimates”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results.

Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward- looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements,including financial outlooks, are intended to provide informationabout management’s current plans and expectations regarding futureoperations, including without limitation, future financingrequirements, and may not be appropriate for other purposes. Certainmaterial factors, estimates or assumptions have been applied in makingforward-looking statements in this news release.

The Company’s actual results coulddiffer materially from those anticipated in the forward-lookingstatements contained in this news release as a result of numerousknown and unknown risks and uncertainties, including withoutlimitation; the risk that the Company’s assumptions may prove to beincorrect; the risk that additional financing may not be obtainable ina timely manner, or at all, and that clinical trials may not commenceor complete within anticipated timelines or the anticipated budget ormay fail; third party suppliers of necessary services or of drugproduct and other materials may fail to perform or be unwilling orunable to supply the Company, which could cause delay or cancellationof the Company’s research and development activities; necessaryregulatory approvals may not be granted or may be withdrawn; theCompany may not be able to secure necessary strategic partner support;general economic conditions, intellectual property and insurancerisks; changes in business strategy or plans; and other risks anduncertainties referred to elsewhere in this news release, any of whichcould cause actual results to vary materially from current results orthe Company’s anticipated future results. Certain of these risks anduncertainties, and others affecting the Company, are more fullydescribed in the Company’s annual management’s discussion andanalysis for the year ended July 31, 2023 under the heading “Risksand Uncertainties” and Helix’s Annual Information Form, inparticular under the headings “Forward-looking Statements” and“Risk Factors”, and other reports filed under the Company’sprofile on SEDAR at www.sedar.com from time to time.Forward-looking statements and information are based on the beliefs,assumptions, opinions and expectations of Helix’s management on thedate of this new release, and the Company does not assume anyobligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required.

Copyright (c) 2024 TheNewswire - All rights reserved.